Patient-centered trials in oncology: Time for a change.
| Autor: | Araujo DV; Medical Oncology Department, Hospital de Base, São José do Rio Preto, Brazil. Electronic address: daniel.araujo@edu.famerp.br., Soler JA; Medical Oncology Department, Hospital de Base, São José do Rio Preto, Brazil., Cordeiro de Lima VC; Medical Oncology Department, AC Camargo Cancer Center, São Paulo, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Med (New York, N.Y.) [Med (N Y)] 2022 Jul 08; Vol. 3 (7), pp. 445-449. |
| DOI: | 10.1016/j.medj.2022.06.007 |
| Abstrakt: | Patient-centered trials are pivotal to advancing the oncology field efficiently. However, in recent years, there has been a shift away from patient-centered approaches. In this commentary, we describe common non-patient-centric practices of contemporary trials, discuss their implications, and propose potential solutions to relocate patients to the center of trials where they belong. Competing Interests: Declaration of interests D.V.A. has an advisory role for MSD and receives honoraria from MSD, Pfizer, GSK, and Libbs. J.A.D. declares no competing interests. V.C.C.L. has an advisory role for MSD, Astra-Zeneca, Lilly, and Janssen; receives honoraria from Amgen, Sanofi, Astra-Zeneca, BMS, MSD, Lilly, Janssen, and Roche; and serves as a consultant for Grupo Hermes Pardini – Medicina de Precisão. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|